Clinical Trial: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Brief Summary: Consolidation treatment for Primary Central Nervous System Diffuse Large B cell Lymphoma(PCNSL)patients remains to be defined.Here we designed a tolerated treatment of HDMTX plus Temozolomide,followed by consolidation with Temozolomide in PCNSL patients.
Detailed Summary:
Sponsor: Guangdong General Hospital
Current Primary Outcome: event free survival [ Time Frame: 3 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Chronic neurotoxicity [ Time Frame: 3 year ]
- Overall survival [ Time Frame: 3 year ]
- Completed response [ Time Frame: 3 year ]
Original Secondary Outcome: Same as current
Information By: Guangdong General Hospital
Dates:
Date Received: October 13, 2016
Date Started: February 2016
Date Completion: February 2019
Last Updated: October 13, 2016
Last Verified: May 2016